2024-05-07 06:05:12
HLBIO’s research and development project of ‘Phase 1 clinical trial for patients with chronic kidney disease of autologous urine-derived stem cell therapy with enhanced kidney treatment effective factors’ is a new project in 2024 eligible for support from the pan-ministerial regenerative medicine technology development project. It was announced that the final selection was made on the 30th.
The pan-ministerial regenerative medical technology development project is a national research and development project in which the Ministry of Science and ICT and the Ministry of Health and Welfare will invest a total of KRW 595.5 billion (KRW 542.3 billion from the government and KRW 53.2 billion from the private sector) by 2030. The project for which HL Bio was selected this time is a stem cell clinical trial project with a project cost of 2.567 billion won (private contribution of 640 million won) over three years.
HL Bio’s ‘KDSTEM Inj.’ is a urine-derived stem cell treatment that enhances kidney treatment function, and is supported by the pan-ministerial regenerative medicine technology development group for new tasks in 2022 (total project cost for 2 years: KRW 1.167 billion) (private contribution of 290 million won)), non-clinical efficacy and safety for chronic kidney disease have been secured, and the Ministry of Food and Drug Safety has approved a phase 1 clinical trial targeting chronic kidney disease patients in May 2023.
Through the selection of new tasks for 2024 by the Pan-Ministry Regenerative Medicine Technology Development Project, HL Bio aims to conduct the world’s first phase 1 clinical trial and enter phase 2 clinical trials for K-Destem, targeting patients with chronic kidney disease, a representative incurable disease. .
Chronic kidney disease is a disease that currently requires dialysis or kidney transplant for which there is no cure worldwide. There is an urgent need to develop a treatment that can fundamentally treat kidney damage. The global chronic kidney disease treatment market is estimated to be worth approximately USD 13.13 billion (KRW 17.44 trillion) in 2023, and will show an average growth rate (CAGR) of 5.6%, reaching approximately USD 19.22 billion (KRW 25.53 trillion) in 2030. ) is expected to rapidly increase in size.
CEO Lee Hong-ki expressed his ambition, saying, “With the selection of this research project, we will accelerate the early completion and commercialization of K-Destem’s domestic clinical trials and enter the global chronic kidney disease treatment market, including the North American and Asia-Pacific markets.”
Choi Yong-seok, Donga.com reporter [email protected]
-
- great
- 0dog
-
- I’m so sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news now
2024-05-07 06:05:12